The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).
 
Kristine Peregrino Lacuna
No Relationships to Disclose
 
Matthew Ingham
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Consulting or Advisory Role - Apexigen; Caris Life Sciences; Daiichi Sankyo; Epizyme; Xencor
Research Funding - Apexigen (Inst); APICES; Astellas Pharma (Inst); AstraZeneca (Inst); Bioatla (Inst); Boehringer Ingelheim (Inst); Intensity (Inst); Merck (Inst); Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
 
Li Chen
Research Funding - Illumina (Inst)
Expert Testimony - Illumina (Inst)
 
Biswajit Das
Research Funding - Illumina (Inst)
 
Shing M Lee
Consulting or Advisory Role - PTC Therapeutics
 
Liner Ge
No Relationships to Disclose
 
Mihaela Druta
Consulting or Advisory Role - AADi; Adaptimmune; Adaptimmune; Decipher Biosciences; Deciphera
Speakers' Bureau - AADi; Deciphera
Travel, Accommodations, Expenses - AADi
 
Anthony Paul Conley
Consulting or Advisory Role - AADi; Applied Clinical Intelligence; Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; Guidepoint Global; InhibRx; Medscape; Nektar; Novartis; OncLive; Schlesinger Associates
Research Funding - Bavarian Nordic (Inst); Chordoma Foundation (Inst); EpicentRx (Inst); Ignyta (Inst); InhibRx (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MedImmune (Inst); NantHealth (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Genentech
 
Mary Louise Keohan
No Relationships to Disclose
 
Mark Agulnik
Consulting or Advisory Role - AADi; Boehringer Ingelheim
Speakers' Bureau - Deciphera
Research Funding - Exelixis (Inst)
 
Melissa Amber Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics
Research Funding - Merck
 
Anna Weinberg Chalmers
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo/Lilly; DePuy Companies (I); ExacTech (I)
Speakers' Bureau - SpringWorks Therapeutics
Research Funding - BioAtla; Boehringer Ingelheim; GlaxoSmithKline; TRACON Pharma
Patents, Royalties, Other Intellectual Property - patent pending for hormone supplementation of tendon and ligament repair (I)
 
Gina Z. D'Amato
Consulting or Advisory Role - Blueprint Medicines; Daiichi Sankyo/Lilly; Deciphera; Epizyme
 
Benjamin Powers
No Relationships to Disclose
 
Mahesh Seetharam
Honoraria - AADi; Daiichi Sankyo; Deciphera; Horizon CME
Travel, Accommodations, Expenses - Horizon CME
 
Brittany L Siontis
Consulting or Advisory Role - Deciphera (Inst)
 
Lorraine Cheryl Pelosof
No Relationships to Disclose
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Iterion Therapeutics, Inc; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; ADRx; Advenchen Laboratories; Agenus; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Boxer Capital LLC; Curis; Daiihi Sankyo; Deciphera; Deciphera Pharmaceuticals,; EcoR1 Capital; Epizyme; Hinge Bio, Inc.; Intellisphere; Kronos Bio, Inc.; PTC Therapeutics; PTC Therapeutics; Putnam Associates; Race Oncology; Regeneron; Salarius Pharmaceuticals, Inc.,
Research Funding - GlaxoSmithKline; Merck; Pfizer; Polaris; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - AADi; Agenus; Astex Pharmaceuticals; Bionaut Labs; Boehringer Ingelheim; Concarlo; Gencirq; Ipsen; January Therapeutics; Kirilys Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Shanghai Pharma
Research Funding - Astex Pharmaceuticals; Oxford BioTherapeutics (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Mia C. Weiss
No Relationships to Disclose